Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non-Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,652
Stocks News & Analysis
stocks
A collection of our best stock opportunities
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
stocks
Undervalued ASX share showing progress in global efforts
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,023.30 | 56.60 | 0.63% |
CAC 40 | 7,857.36 | 56.48 | 0.72% |
DAX 40 | 24,217.37 | 247.01 | 1.03% |
Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
FTSE 100 | 9,136.32 | 54.88 | 0.60% |
HKSE | 25,473.40 | 51.05 | -0.20% |
NASDAQ | 21,098.29 | 80.29 | -0.38% |
Nikkei 225 | 40,682.14 | 7.59 | 0.02% |
NZX 50 Index | 12,961.28 | 24.87 | 0.19% |
S&P 500 | 6,370.86 | 18.91 | -0.30% |
S&P/ASX 200 | 8,764.10 | 59.50 | 0.68% |
SSE Composite Index | 3,632.41 | 22.70 | 0.63% |